Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study

被引：0
|
作者：
Richardson, P. G.
Chanan-Khan, A.
Lonial, S.
Krishnan, A.
Carroll, M.
Alsina, M.
Albitar, M.
Berman, D.
Kaplita, S.
Anderson, K.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[3] Emory Univ, Sch Med, Atlanta, GA 30322 USA
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Sutter Reg Canc Inst, Sacramento, CA USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[7] Nichols Inst, San Juan Capistrano, CA USA
[8] Bristol Myers Squibb Co, Princeton, NJ USA
[9] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8503
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma
    Voorhees, Peter M.
    Gasparetto, Cristina
    Moore, Dominic T.
    Winans, Diane
    Orlowski, Robert Z.
    Hurd, David D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (07): : 424 - 432
  • [22] Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
    Badros, Ashraf
    Burger, Angelika M.
    Philip, Sunita
    Niesvizky, Ruben
    Kolla, Sarah S.
    Goloubeva, Olga
    Harris, Carolynn
    Zwiebel, James
    Wright, John J.
    Espinoza-Delgado, Igor
    Baer, Maria R.
    Holleran, Julianne L.
    Egorin, Merrill J.
    Grant, Steven
    CLINICAL CANCER RESEARCH, 2009, 15 (16) : 5250 - 5257
  • [23] Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, plus /- bortezomib, in patients with relapsed/refractory multiple myeloma.
    Kaufman, Jonathan L.
    Baz, Rachid C.
    Harrison, Simon J.
    Quach, Hang
    Ho, Shir-Jing
    Vangsted, Annette J.
    Moreau, Philippe
    Gibbs, Simon D. J.
    Salem, Ahmed H.
    Coppola, Sheryl
    Ross, Jeremy A.
    Masud, Abdullah A.
    Westrup, Sally
    Vue, Jenny
    Maciag, Paulo Cesar
    Bueno, Orlando
    Bahlis, Nizar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma
    Yoshiaki Ogawa
    Michinori Ogura
    Kensei Tobinai
    Kiyoshi Ando
    Tatsuya Suzuki
    Takashi Watanabe
    Ken Ohmachi
    Toshiki Uchida
    Mary E. Hanson
    Yoshinobu Tanaka
    Yasuhiro Koh
    Takashi Shimamoto
    Tomomitsu Hotta
    International Journal of Hematology, 2016, 103 : 25 - 33
  • [25] Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
    Jakubowiak, A. J.
    Benson, D. M., Jr.
    Bensinger, W.
    Siegel, D. S.
    Zimmerman, T. M.
    Mohrbacher, A.
    Richardson, P. G.
    Afar, D.
    Singhal, A. K.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma
    Ogawa, Yoshiaki
    Ogura, Michinori
    Tobinai, Kensei
    Ando, Kiyoshi
    Suzuki, Tatsuya
    Watanabe, Takashi
    Ohmachi, Ken
    Uchida, Toshiki
    Hanson, Mary E.
    Tanaka, Yoshinobu
    Koh, Yasuhiro
    Shimamoto, Takashi
    Hotta, Tomomitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (01) : 25 - 33
  • [27] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Victoria Mateos, Maria
    Prosper, Felipe
    Martin Sanchez, Jesus
    Ocio, Enrique M.
    Oriol, Albert
    Motllo, Cristina
    Michot, Jean-Marie
    Jarque, Isidro
    Iglesias, Rebeca
    Sole, Maria
    Martinez, Sara
    Kahatt, Carmen
    Fudio, Salvador
    Corral, Gema
    Zeaiter, Ali
    Montilla, Lola
    Ribrag, Vincent
    CANCER MEDICINE, 2023, 12 (04): : 3999 - 4009
  • [28] Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib
    Richardson, Paul
    Wolf, Jeffrey
    Jakubowiak, Andrzej
    Zonder, Jeffrey
    Lonial, Sagar
    Irwin, David H.
    Densmore, John
    Krishnan, Amrita
    Raje, Noopur
    Bar, Michael H.
    Allerton, Jeffrey P.
    Schlossman, Robert
    Ghobrial, Irene M.
    Munshi, Nikhil C.
    Martin, Thomas
    Laubach, Jacob
    Colson, Kathy
    Dean, Sarah
    Tocco, Deanna
    Steinfield, Elizabeth
    Kendall, Tara
    O'Riley, Kimberly
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Anderson, Kenneth C.
    BLOOD, 2008, 112 (11) : 321 - 322
  • [29] Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study
    Voorhees, Peter M.
    Gasparetto, Cristina
    Richards, Kristy L.
    Garcia, Reynaldo
    Strader, John S.
    Ferraro, Madlyn
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic T.
    Dodd, Andrew
    Foster, Matthew C.
    Gabriel, Don A.
    Shea, Thomas C.
    Serody, Jonathan
    van Deventer, Hendrik W.
    Rizvi, Syed
    Orlowski, Robert Z.
    Hurd, David D.
    BLOOD, 2009, 114 (22) : 129 - 130
  • [30] Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: A phase I/II study.
    Berenson, J
    Yang, H
    Swift, R
    Sadler, K
    Vescio, R
    Adams, J
    Schenkein, D
    BLOOD, 2004, 104 (11) : 64A - 64A
12345